Charles River Associates recently undertook an evidence-based analysis of the benefits of personalised medicine (PM) and found considerable evidence of the potential benefits for patients, clinicians and healthcare systems. However, significant barriers continue to hinder the adoption of PM in Europe. The analysis was undertaken on behalf of the European Biopharmaceutical Enterprises (EBE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Our conclusions are based on a case study approach focusing primarily on oncology, examining experiences in five European markets (Denmark, England, France, the Netherlands and Poland), and supplemented by interviews with payers, policymakers and healthcare professionals to understand the access landscape for PM. We composed five policy recommendations to encourage the development of PM and incentivise more equitable uptake.
Click below to download a summary of our report.
To read the full report on the EFPIA web site, click here.
An accompanying presentation is available here.
Impact of the EU's general pharmaceutical legislation on Europe's innovation ecosystem and biotechnology companies
EuropaBio asked Charles River Associates to research the potential impact of the proposed changes included within the EU’s General Pharmaceutical Legislation...